Friday, August 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Maintains Positive Outlook on Endava with Adjusted Price Target

Elaine Mendonca by Elaine Mendonca
March 1, 2024
in Breaking News
0
Biotechnology Stock Bull Market
0
SHARES
22
VIEWS
Share on FacebookShare on Twitter

TD Cowen analyst Bryan Bergin has reiterated his positive outlook on Endava (NYSE: DAVA), maintaining an Outperform rating. However, he has adjusted the price target to $52, down from $85. Despite this revision, the average one-year price target for Endava plc – ADR stands at $72.80, with projections ranging from $53.53 to $98.48.

Analysts surveyed by Capital IQ also give Endava an average outperform rating, with a price target range of $53 to $98.48. The company offers technology services and solutions across various industries including payments, financial services, technology, media, telecom, consumer products, retail, mobility, and healthcare.

Endava leverages its Distributed Enterprise Agile scaling framework to help clients develop digital solutions and maximize their business opportunities.

DAVA Stock Plummets 41.76% on March 1, 2024: Pre-Market Gains Offer Hope for Recovery

On March 1, 2024, DAVA stock experienced a significant drop in price, with shares decreasing by $26.65 since the market last closed. This represents a 41.76% drop in value, with the stock closing at $37.17. However, there seems to be some positive movement in pre-market trading, as the stock has risen by $0.72.

Investors and analysts will be closely monitoring DAVA’s performance in the coming days to see if the pre-market gains will hold and if the stock can start to recover from its recent losses. It will be important to watch for any news or developments that could impact the stock’s price movement.

DAVA Stock Analysis: Mixed Performances on March 1, 2024

On March 1, 2024, DAVA stock experienced mixed performances based on the financial data provided by CNN Money. The total revenue for the company stood at $955.89 million for the past year, showing a 9.84% increase compared to the previous year. However, the total revenue for the second quarter was $227.72 million, reflecting a 4.5% decrease compared to the previous quarter.

Similarly, the net income for DAVA was reported at $113.26 million for the past year, holding flat compared to the previous year. However, the net income for the second quarter was $10.36 million, indicating a significant 33.83% decrease compared to the previous quarter.

Furthermore, the earnings per share (EPS) for DAVA stock was $1.95 for the past year, remaining flat compared to the previous year. However, the EPS for the second quarter was $0.18, showing a substantial 34.3% decrease compared to the previous quarter.

Overall, the financial performance of DAVA stock on March 1, 2024, was a mix of positive and negative indicators. Investors and analysts will closely monitor these financial indicators to assess the overall health and performance of DAVA stock in the coming months. It is essential for investors to conduct thorough research and analysis before making any investment decisions based on the financial data provided.

Tags: DAVA
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Ai Sleeping

Sleep Quality's Impact on Physical and Financial Well-Being

DVY stock news

Truist Securities Analyst Reiterates Hold Recommendation on Best Buy Co

Finances (2)

Truist Securities Analyst Maintains Hold Rating on Integra Lifesciences with Revised Price Target

Recommended

Palantir Stock

Palantir Shares Face Valuation Pressures Despite Strong Earnings

9 months ago
BridgeBio Pharma Stock

BridgeBio Pharma Investors Await Critical Heart Drug Data

9 months ago
Ocugen Stock

Ocugen’s Fresh $130M Cushion Sets the Stage for a Data-Heavy July and a Pivotal Regulatory Filing

1 month ago
Airbnb Stock

Navigating Regulatory Headwinds and Innovation: Airbnb’s Strategic Crossroads

10 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly FALLBACK Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Realty Income Robinhood Rocket Lab USA Salesforce Strategy Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Kioxia’s Unsettling Arithmetic: Record Profits, a $229 Million Verdict, and a Stock Still Searching for Its Floor

French Top Court Settles Disputes Over Expert Fees, Strike Notices and the AGS Wage Guarantee

MSCI World ETF: Index Provider Rewrites the Rulebook for Fast-Moving Stocks

Airbus’ Paradox: A Slightly Smaller Forecast That Nobody Seems to Mind

Almonty Industries Rebounds From Index-Driven Exit as Tungsten Calculus Shifts Westward

OHB’s Two-Faced Half-Year: Record Orders Mask a Profit Squeeze That Spooked the Market

Trending

Nel ASA Stock
Analysis

Nel ASA’s Two-Speed Story: Orders Accelerate While the P&L Keeps Bleeding

by Jackson Burston
August 7, 2026
0

The Norwegian electrolyser maker Nel ASA is living a split-screen reality. Its order intake just exploded by...

SANDISK Stock

SanDisk’s $94 Billion Backlog Can’t Bridge the Gap Between Record Results and a Disappointed Market

August 7, 2026
Bitcoin Stock

Payrolls Shrink, Rate-Cut Bets Return, and Crypto’s Plumbing Wins

August 7, 2026
Kioxia Stock

Kioxia’s Unsettling Arithmetic: Record Profits, a $229 Million Verdict, and a Stock Still Searching for Its Floor

August 7, 2026
FALLBACK Stock

French Top Court Settles Disputes Over Expert Fees, Strike Notices and the AGS Wage Guarantee

August 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Nel ASA’s Two-Speed Story: Orders Accelerate While the P&L Keeps Bleeding
  • SanDisk’s $94 Billion Backlog Can’t Bridge the Gap Between Record Results and a Disappointed Market
  • Payrolls Shrink, Rate-Cut Bets Return, and Crypto’s Plumbing Wins

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com